A novel role of interleukin-13 receptor α2 in pancreatic cancer invasion and metastasis

Cancer Research

Volumn 69, Issue 22, 2009, Pages 8678-8685

  Fujisawa, Toshio ^a   Joshi, Bharat ^a   Nakajima, Atsushi ^b   Puri, Raj K ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA2; MATRIGEL; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NUCLEAR FACTOR; STAT6 PROTEIN; TRANSCRIPTION FACTOR AP 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CACHEXIA; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMPLANTATION; IN VIVO STUDY; LIVER METASTASIS; LYMPH NODE METASTASIS; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PERITONEUM; PERITONEUM METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; HUMANS; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; MATRIX METALLOPROTEINASES; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 72249115096     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2100     Document Type: Article

References (35)

1. Bramhall SR. Stromal degradation by the malignant epithelium in pancreatic cancer and the therapeutic potential of proteolytic inhibition. J Hepatobiliary Pancreat Surg 1998;5:392-401.
2. Mollenhauer J, Roether I, Kern HF. Distribution of extracellular matrix proteins in pancreatic ductal adenocarcinoma and its influence on tumor cell proliferation in vitro. Pancreas 1987;2:14-24. (Pubitemid 18189807)
3. Johnsen M, Lund LR, Romer J, Almholt K, Dano K. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 1998;10:667-671 (Pubitemid 28477027)
4. Basset P, Okada A, Chenard MP, et al. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol 1997;15:535-541 (Pubitemid 27190028)
5. Bloomston M, Zervos EE, Rosemurgy AS II. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol 2002;9:668-674 (Pubitemid 34857984)
6. Kajita M, Itoh Y, Chiba T, et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 2001;153:893-904. (Pubitemid 34289231)
7. Benbow U, Brinckerhoff CE. The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol 1997;15:519-526
8. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999;13:781-792 (Pubitemid 29220691)
9. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-186
10. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998; 74:49-139. (Pubitemid 28193546)
11. Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK. Interleukin-13 receptor α2 chain: a potential biomarker and molecular target for ovarian cancer therapy. Cancer 2006;107:1407-1418 (Pubitemid 44452792)
12. Kornmann M, Kleeff J, Debinski W, Korc M. Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4. Anticancer Res 1999; 19:125-131 (Pubitemid 29168228)
13. Vallera DA, Stish BJ, Shu Y, et al. Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model. Gut 2008;57:634-641 (Pubitemid 351579977)
14. Joshi BH, Hogaboam C, Dover P, Husain SR, Puri RK. Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases. Vitam Horm 2006;74:479-504.
15. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002;109 Suppl:S121-31.
16. Kawakami K, Taguchi J, Murata T, Puri RK. The interleukin-13 receptor α2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 2001;97:2673-2679
17. Chiaramonte MG, Mentink-Kane M, Jacobson BA, et al. Regulation and function of the interleukin 13 receptor α2 during a T helper cell type 2-dominant immune response. J Exp Med 2003;197:687-701. (Pubitemid 36350864)
18. Rahaman SO, Sharma P, Harbor PC, Aman MJ, Vogelbaum MA, Haque SJ. IL-13Rα2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res 2002;62:1103-1109 (Pubitemid 34160294)
19. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis. Nat Med 2006;12:99-106. (Pubitemid 43050083)
20. Joshi BH, Plautz GE, Puri RK. Interleukin-13 receptor α chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 2000;60:1168-1172
21. Kawakami M, Kawakami K, Kasperbauer JL, et al. Interleukin-13 receptor α2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin Cancer Res 2003;9:6381-6388 (Pubitemid 38031823)
22. Puri RK, Leland P, Obiri NI, et al. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 1996;87:4333-4339 (Pubitemid 26155030)
23. Husain SR, Obiri NI, Gill P, et al. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin Cancer Res 1997;3: 151-156 (Pubitemid 27107288)
24. Joshi BH, Leland P, Puri RK. Identification and characterization of interleukin-13 receptor in human medulloblastoma and targeting these receptors with interleukin-13-Pseudomonas exotoxin fusion protein. Croat Med J 2003;44:455-462 (Pubitemid 37092805)
25. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436: 518-524
26. Joshi BH, Puri RK. Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli. Protein Expr Purif 2005;39:189-198
27. Kawakami K, Terabe M, Kawakami M, Berzofsky JA, Puri RK. Characterization of a novel human tumor antigen interleukin-13 receptor α2 chain. Cancer Res 2006; 66:4434-4442
28. Murata T, Obiri NI, Debinski W, Puri RK. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun 1997;238:90-94 (Pubitemid 27453280)
29. Jones LJ, Upson RH, Haugland RP, Panchuk-Voloshina N, Zhou M. Quenched BODIPY dye-labeled casein substrates for the assay of protease activity by direct fluorescence measurement. Anal Biochem 1997;251: 144-152 (Pubitemid 27392671)
30. Formentini A, Prokopchuk O, Strater J, et al. Interleukin-13 exerts autocrine growth-promoting effects on human pancreatic cancer, and its expression correlates with a propensity for lymph node metastases. Int J Colorectal Dis 2009;24:57-67.
31. Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008;40: 1362-1378
32. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007;211:19-26. (Pubitemid 46363892)
33. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-1912
34. Lee PJ, Zhang X, Shan P, et al. ERK1/2 mitogen-activated protein kinase selectively mediates IL-13-induced lung inflammation and remodeling in vivo. J Clin Invest 2006;116:163-173 (Pubitemid 43121801)
35. Kawakami K, Kawakami M, Snoy PJ, Husain SR, Puri RK. In vivo overexpression of IL-13 receptor α2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med 2001;194: 1743-1754